Distribuzione geografica
Continente #
NA - Nord America 4.780
EU - Europa 1.922
AS - Asia 801
SA - Sud America 13
AF - Africa 7
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 6
Totale 7.535
Nazione #
US - Stati Uniti d'America 4.768
CN - Cina 458
PL - Polonia 453
IT - Italia 382
UA - Ucraina 368
DE - Germania 254
HK - Hong Kong 184
FI - Finlandia 155
IE - Irlanda 94
GB - Regno Unito 87
FR - Francia 48
VN - Vietnam 46
SG - Singapore 43
IN - India 27
RU - Federazione Russa 19
TR - Turchia 16
SE - Svezia 15
BE - Belgio 12
CA - Canada 10
BR - Brasile 7
NL - Olanda 7
EU - Europa 6
GR - Grecia 6
JP - Giappone 6
AU - Australia 5
MA - Marocco 4
BD - Bangladesh 3
CZ - Repubblica Ceca 3
HU - Ungheria 3
ID - Indonesia 3
TN - Tunisia 3
AM - Armenia 2
AR - Argentina 2
AT - Austria 2
EC - Ecuador 2
IR - Iran 2
KR - Corea 2
PT - Portogallo 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
AZ - Azerbaigian 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ES - Italia 1
IL - Israele 1
IS - Islanda 1
JM - Giamaica 1
KH - Cambogia 1
KW - Kuwait 1
LK - Sri Lanka 1
LV - Lettonia 1
MD - Moldavia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PE - Perù 1
SI - Slovenia 1
Totale 7.535
Città #
Fairfield 701
Ashburn 493
Warsaw 451
Woodbridge 442
Houston 332
Chandler 312
Seattle 301
Jacksonville 281
Cambridge 275
Wilmington 243
Ann Arbor 189
Hong Kong 182
Princeton 165
New York 164
Dearborn 146
Helsinki 135
Dublin 92
Brescia 91
Beijing 86
Nanjing 74
Shanghai 63
Dong Ket 46
Milan 40
Boardman 37
San Diego 37
Washington 31
Des Moines 30
Nanchang 28
Shenyang 26
Singapore 24
Changsha 21
Jinan 21
Hebei 20
Verona 19
Los Angeles 17
Kunming 16
London 15
Jiaxing 13
Brussels 12
Lancaster 11
Ningbo 11
Zhengzhou 11
Kocaeli 10
Redwood City 10
San Francisco 10
Hangzhou 8
Iseo 8
Tianjin 8
Toronto 8
Haikou 7
Kilburn 7
Rome 7
Taizhou 7
Athens 6
Ceto 6
Lumezzane 6
New Bedfont 6
Nürnberg 6
Phoenix 6
Chiswick 5
Hefei 5
Lappeenranta 5
Orange 5
Vignate 5
Chongqing 4
Cremona 4
Falls Church 4
Leawood 4
Pune 4
San Mateo 4
Changchun 3
Chicago 3
Delhi 3
Dhaka 3
Florence 3
Frankfurt am Main 3
Hanover 3
Monza 3
Reggio Emilia 3
Rio De Janeiro 3
Siena 3
Solbiate Olona 3
Sydney 3
Tokyo 3
Wandsworth 3
Amsterdam 2
Ardabil 2
Augusta 2
Bangkok 2
Bologna 2
Bratislava 2
Böblingen 2
Casablanca 2
Como 2
Dallas 2
Deiva Marina 2
Falkenstein 2
Ferrara 2
Furnari 2
Grassobbio 2
Totale 5.954
Nome #
Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study 200
Overexpression of sialidase NEU3 increases the cellular radioresistance potential of U87MG glioblastoma cells 191
Light and shadows of a new technique: Isphoton total-skin irradiation using helical IMRT feasible, less complex and as toxic as the electrons one? 175
Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy 175
Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review 160
Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study 156
Resected pN1 non-small cell lung cancer: recurrence patterns and nodal risk factors may suggest selection criteria for post-operative radiotherapy 151
Pros-IT CNR: an Italian prostate cancer monitoring project 146
Reirradiation in head and neck recurrent or second primary tumor: efficacy, safety, and prognostic factors 144
Post-surgical therapeutic approaches to glioblastoma patients submitted to biopsy (BA) or "partial" resection (PR): the possibilities to treat also them without renunciations. Study from the Brescia Neuro-Oncology Group 141
Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial 138
The treatment of patients with 1-3 brain metastases: is there a place for whole brain radiotherapy alone, yet? A retrospective analysis 135
A national multicenter study on 1072 DCIS patients treated with breast-conserving surgery and whole breast radiotherapy (COBCG-01 study) 133
A neuro-oncologic challenge: the case of a large, aggressive, malignant meningioma of the skull base with paranasal sinus involvement 133
Reply to 'Comment on 'Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study'' 128
Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer 125
Oligometastatic prostate cancer patients stratification: A molecular signature identified by liquid biopsy 125
Stereotactic ablative radiation therapy in renal cell carcinoma: From oligometastatic to localized disease. 122
Role of external beam radiotherapy in the treatment of relapsing meningioma 120
Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial 118
Primary cutaneous non-Hodgkin lymphoma: results of a retrospective analysis in the light of the recent ILROG guidelines 117
Mebendazole as a candidate for drug repurposing in oncology: An extensive review of current literature 117
Radiotherapy for adult medulloblastoma: Long term result from a single institution. A review of prognostic factors and why we do need a multi-institutional cooperative program 114
Whole brain radiotherapy with adjuvant or concomitant boost in brain metastasis: dosimetric comparison between helical and volumetric IMRT technique 113
Salvage Low Dose Rate Brachytherapy For Recurrent Prostate Cancer After External Beam Radiotherapy: Results From A Single Institution With Focus On Toxicity And Functional Outcomes 107
Postoperative radiotherapy for prostate cancer: the sooner the better and potential to reduce toxicity even further 107
Retreatment of recurrent adult medulloblastoma with radiotherapy: a case report and review of the literature. 106
Pattern of relapse of glioblastoma multiforme treated with radical radio-chemotherapy: Could a margin reduction be proposed? 105
Radiation Tolerance of Normal Brain: QUANTEC 2010 and Beyond 104
From Molecular to Clinical Radiation Biology of Glioblastoma 102
Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature 102
Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study 102
Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience 100
Analysis of Circulating Tumor Cells in Prostate Cancer Patients at PSA Recurrence and Review of the Literature 99
Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study 95
Differential Diagnosis and Clinical Management of a Case of COVID-19 in a Patient With Stage III Lung Cancer Treated With Radio-chemotherapy and Durvalumab 93
The growing role of biology in the treatment of glioblastoma: no more one kind of disease 91
Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy 91
Cetuximab and Radiation Therapy in Head and Neck Cancer 90
GUROPA survey: genito-urinary radiation oncology prescription attitudes 88
Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO) 87
Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy 87
Exploring the role of enzalutamide in combination with radiation therapy: An in vitro study 86
Impact of Surgical Approach on Patient-Reported Outcomes after Radical Prostatectomy: A Propensity Score-Weighted Analysis from a Multicenter, Prospective, Observational Study (The Pros-IT CNR Study) 85
Two months of radiation oncology in the heart of Italian “red zone” during COVID-19 pandemic: paving a safe path over thin ice 84
Three-dimensional conformal radiotherapy, static intensity-modulated and helical intensity-modulated radiotherapy in glioblastoma. Dosimetric comparison in patients with overlap between target volumes and organs at risk. 84
Circulating Tumour Cells in Clinical Practice: Can Lessons Learned From Locally Advanced/Metastatic Breast and Prostate Cancers Guide Their use for other Cancer Types? Lights and Shadows 81
Stereotactic Radiation Therapy of Lung Cancers and Subsequent Parenchymal Alterations: from Their Spatial Distribution to the Use in Clinical Practice 77
Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events 75
Applying radiation protection and safety in radiotherapy 73
A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients 73
A simplified integrated molecular and immunohistochemistry-based algorithm allows high accuracy prediction of glioblastoma transcriptional subtypes 71
The “Radioresistance” of Glioblastoma in the Clinical Setting, and the Present Therapeutic Options 69
When Less Is More: Specific Capture and Analysis of Tumor Exosomes in Plasma Increases the Sensitivity of Liquid Biopsy for Comprehensive Detection of Multiple Androgen Receptor Phenotypes in Advanced Prostate Cancer Patients 68
The impact of tumor histology and recursive partitioning analysis classification on the prognosis of patients treated with whole-brain hypofractionated radiotherapy for brain metastases: analysis of 382 patients 65
Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR) 65
The linguistic validation process of the Vanderbilt Head and Neck Symptom Survey - Italian Version (VHNSS-IT) 63
Non-metastatic ductal adenocarcinoma of the prostate: pattern of care from an uro-oncology multidisciplinary group 60
How radical prostatectomy procedures have changed over the last 10 years in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study 59
Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study 56
Caveolin-1 promotes radioresistance in rhabdomyosarcoma through increased oxidative stress protection and DNA repair 55
Letter to the editor regarding “Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable” 54
A pilot study on the Vanderbilt head and neck symptom survey Italian version (VHNSS-IT) to test its feasibility and utility in routine clinical practice 50
Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer 50
Metastasis-directed Therapy (SBRT) Guided by PET-CT 18F-CHOLINE Versus PET-CT 68Ga-PSMA in Castration-sensitive Oligorecurrent Prostate Cancer: A Comparative Analysis of Effectiveness 47
Stereotactic radiotherapy with simultaneous integrated protection planning technique for synovial sarcoma with stomach abutment: A case report of a complete response 45
Stereotactic prostate radiotherapy with or without androgen deprivation therapy, study protocol for a phase III, multi-institutional randomized-controlled trial 44
Radiotherapy for the treatment of solitary plasmacytoma: 7-year outcomes by a mono-institutional experience 43
PROLAPSE: survey about local prostate cancer relapse salvage treatment with external beam re-irradiation: results of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) 41
RR Myelo POINT: A Retrospective Single-Center Study Assessing the Role of Radiotherapy in the Management of Multiple Myeloma and Possible Interactions with Concurrent Systemic Treatment 40
A Systematic Review on Intensity Modulated Radiation Therapy for Mediastinal Hodgkin's Lymphoma 39
Radiation therapy during the coronavirus disease 2019 (covid-19) pandemic in Italy: A view of the nation's young oncologists 37
Health-related quality of life 24-month after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study 35
Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study 33
Anal squamous cell carcinoma: Impact of radiochemotherapy evolution over years and an explorative analysis of MRI prediction of tumor response in a mono-institutional series of 131 patients 33
Hyperactive Akt1 Signaling Increases Tumor Progression and DNA Repair in Embryonal Rhabdomyosarcoma RD Line and Confers Susceptibility to Glycolysis and Mevalonate Pathway Inhibitors 32
Low-dose Lung Radiotherapy for COVID-19-related Pneumonia: Preliminary Results of the Italian Mono-institutional COLOR-19 Trial 31
Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience 30
'Le Roi est mort, vive le Roi': New Roles of Radiotherapy in the Treatment of Lymphomas in Combination With Immunotherapy 28
Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy 26
Pattern of Recurrence After Stereotactic Radiotherapy in Prostate Cancer Patients With Nodal Pelvic Relapse. A Multi-Institutional Retrospective Analysis 24
PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study 24
OLIGO-AIRO: a national survey on the role of radiation oncologist in the management of OLIGO-metastatic patients on the behalf of AIRO 23
Combining abiraterone and radiotherapy in metastatic castration-resistant prostate cancer: a review of current evidence 23
Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance 23
Effect of Degarelix administration on bone health in prostate cancer patients without bone metastases. The Blade study 22
Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation 20
Stereotactic Radiotherapy for Localised Prostate Cancer: Time to Clarify the Possible Impact of Concurrent Androgen Deprivation Therapy 20
Achieving Consensus for Management of Hormone-Sensitive, Low-Volume Metastatic Prostate Cancer in Italy 17
Long-term outcome of re-irradiation for recurrent or second primary head and neck cancer: A multi-institutional study of AIRO-Head and Neck working group 14
null 13
Prostate Cancer Treatment-Related Toxicity: Comparison between 3D-Conformal Radiation Therapy (3D-CRT) and Volumetric Modulated Arc Therapy (VMAT) Techniques 13
Salvage Stereotactic Reirradiation for Local Recurrence in the Prostatic Bed After Prostatectomy: A Retrospective Multicenter Study 13
Radiotherapy at oligoprogression for metastatic castration-resistant prostate cancer patients: a multi-institutional analysis 12
Upfront metastasis‑directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance: in response to Onal's letter to the editor 11
Impact of Gastrointestinal Side Effects on Patients' Reported Quality of Life Trajectories after Radiotherapy for Prostate Cancer: Data from the Prospective, Observational Pros-IT CNR Study 11
Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative setting 10
How Has Prostate Cancer Radiotherapy Changed in Italy between 2004 and 2011? An Analysis of the National Patterns-Of-Practice (POP) Database by the Uro-Oncology Study Group of the Italian Society of Radiotherapy and Clinical Oncology (AIRO) 9
Totale 7.717
Categoria #
all - tutte 39.162
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.162

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019151 0 0 0 0 0 0 0 0 0 0 0 151
2019/20201.960 201 80 75 164 126 278 253 218 165 212 79 109
2020/20211.753 62 171 93 181 92 225 78 170 141 263 142 135
2021/2022751 65 100 26 28 12 49 31 67 39 83 38 213
2022/2023878 97 35 34 52 90 186 13 106 157 5 64 39
2023/20241.260 69 28 165 75 71 302 50 89 206 49 65 91
Totale 7.763